839 Dual Targeting Autoinflammation and PD-L1/L2 Immune Checkpoint by EGCG Augments Anti-Tumor Effects in Melanoma

Journal of Investigative Dermatology - United Kingdom
doi 10.1016/j.jid.2019.03.915
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

Targeting NKT Cells and PD-L1 Pathway Results in Augmented Anti-Tumor Responses in a Melanoma Model

Cancer Immunology, Immunotherapy
Cancer ResearchMedicineOncologyAllergyImmunology
2011English

Elimination of Tumor by CD47/PD-L1 Dual-Targeting Fusion Protein That Engages Innate and Adaptive Immune Responses

mAbs
AllergyImmunology
2017English

PD-L1 Checkpoint Blockade Delivered by Retroviral Replicating Vector Confers Anti-Tumor Efficacy in Murine Tumor Models

Oncotarget
Oncology
2019English

Regorafenib Promotes Anti-Tumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2019English

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Breast Care
SurgeryOncology
2016English

FcγRs Modulate the Anti-Tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Cancer Cell
Cancer ResearchOncologyCell Biology
2015English

Crosslink Between Temozolomide and PD-L1 Immune-Checkpoint Inhibition in Glioblastoma Multiforme

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

PD-L1 Expression by Tumor Cell-Lines: A Predictive Marker in Melanoma

Experimental Dermatology
BiochemistryDermatologyMolecular Biology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy